Compare Barclays PLC (BCS) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Quest Diagnostics Inc — how do they compare? Barclays PLC trades at $28 (market cap $93.87B), while Quest Diagnostics Inc trades at $237.5 (market cap $26.21B). The key difference: Barclays PLC is far larger — about 3.6× Quest Diagnostics Inc's market cap, and Barclays PLC pays the higher dividend (2.19%). Which is the better fit depends on your goals.
| BCS | DGX | |
|---|---|---|
Market Cap | $93.87B | $26.21B |
Sector | Financials | Health |
52-Week High | $28.56 | $238.50 |
52-Week Low | $19.36 | $173.49 |
Dividend Yield | 2.19% | 1.45% |
Enterprise Value | — | $31.97B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
